Bristol-Myers Squibb Co (NYSE:BMY) traded at $46.84 at close of the session on Friday, June 20 and made an upward move of 46.86% on its previous day’s price.
Bristol-Myers Squibb Co has a market cap of $95.36 billion and is expected to release its quarterly earnings report on 2025-Apr-24. With its Forward Dividend at 2.48 and a yield of 5.30%, the company’s investors could be anxious for the BMY stock to gain ahead of the earnings release.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 11.32B, with a low of 11.11B and a high of 11.57B. The median projection represents growth adding up to -7.25% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 46.16B, or -4.42% down from figures reported last year.
Based on estimates by 14 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 9 have rated the Bristol-Myers Squibb Co (BMY) stock as a Hold, while 5 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Hold and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the BMY stock currently stands at 0.24, and the current price level is 34100 off its SMA20 and 2.73 from its 50-day simple moving average. The beta value is -35.69%, while the average true range (ATR) is currently pointing at -14.95%. The average price target for the stock over the next 12 months is $66.5, with the estimates having a low of $65 and a high of $68. These price ends are -38.77% and -45.18% off the current price level respectively, although investors could be excited at the prospect of a -41.97% if the BMY share price touches on the median price of $66.5.
